RE:$$ ; Your absolutely right. I just made a full review of their potential value considering no debt, "sleekly clean" books etc. Depending on the ratios you look at for IT they are already a great buy at up to 0,24$.
Then depending on the value that can be added to the COVID testing we can add between 0$ to 1,32$ (10X sales/shares for COVID testing) right now. This is the insurance policy no other stock offers.
It won't stop soon so these shares are a bargain now.
if they succeed to add a few AI contracts, that we see in the pipeline I reasonably see the AI component valued a 1,00$-1,50$ next spring. Add the cash flow generated by COVID testing or a scenario of continued testing at least up to the end of 2022 and I will believe in this company reaching 2$ before year end 2022. These represents my own assessment based. Please DYODD.
have a great weekend!